cbdMD sees FY25 revenue $19.1M-$19.3M vs. $19.5M last year

Net Loss for fiscal 2025 is expected to improve from ($3.7M) to a range of between($1.9M)-($2.1M). “Over the past year, cbdMD (YCBD) has taken decisive action to strengthen the business, sharpen our operating model, and create a more stable foundation for long-term growth. These efforts are reflected in our results. While many of our public peers reported 8-10% declines in our fiscal fourth quarter and trailing twelve months, we achieved positive sequential and year over year revenue growth in the fourth quarter and essentially flat year-over-year sales, a clear sign that our strategy is taking hold. We expect continued earnings improvement for fiscal 2025 over 2024, driven by disciplined cost management and a focus on profitable growth. I’m proud of our team’s performance this year and the momentum we are building across the organization. As we look ahead to our mid-December earnings call, we are energized by what we’ve accomplished and confident in our ability to steer a path forward. Our team has a multi-year track record of improving the business, and we remain relentless in our commitment to navigating a complex environment and delivering a durable, long-term business for shareholders,” said Ronan Kennedy, CEO & CFO of cbdMD.